Literature DB >> 2190315

Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.

R J Orentas1, J E Hildreth, E Obah, M Polydefkis, G E Smith, M L Clements, R F Siliciano.   

Abstract

Cytolytic T lymphocyte (CTL) responses were evaluated in humans immunized with recombinant human immunodeficiency virus type 1 (HIV) envelope glycoprotein gp160. Some vaccinees had gp160-specific CTLs that were shown by cloning to be CD4+. Although induced by exogenous antigen, most gp160-specific CTL clones also recognized gp160 synthesized endogenously in target cells. These clones lysed autologous CD4+ T lymphoblasts infected with HIV. Of particular interest were certain vaccine-induced clones that lysed HIV-infected cells, recognized gp160 from diverse HIV isolates, and did not participate in "innocent bystander" killing of noninfected CD4+ T cells that had bound gp120.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190315     DOI: 10.1126/science.2190315

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  48 in total

Review 1.  Prospects for immune reconstitution in HIV-1 infection.

Authors:  N Imami; F Gotch
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

2.  Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines.

Authors:  Barbara Lotti; Thomas Wendland; Hansjakob Furrer; Nikhil Yawalkar; Salome von Greyerz; Karin Schnyder; Marlène Brandes; Pietro Vernazza; Ralf Wagner; Thi Nguyen; Eric Rosenberg; Werner J Pichler; Christian Brander
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

3.  Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes.

Authors:  L C Dai; K West; R Littaua; K Takahashi; F A Ennis
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

Review 4.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

5.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

6.  Cytotoxic activity against maedi-visna virus-infected macrophages.

Authors:  W C Lee; I McConnell; B A Blacklaws
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates.

Authors:  M J Irwin; L S Laube; V Lee; M Austin; S Chada; C G Anderson; K Townsend; D J Jolly; J F Warner
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1.

Authors:  M J McElrath; M Rabin; M Hoffman; S Klucking; J V Garcia; P D Greenberg
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes.

Authors:  S Chada; C E DeJesus; K Townsend; W T Lee; L Laube; D J Jolly; S M Chang; J F Warner
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates.

Authors:  K Schlienger; M Mancini; Y Rivière; D Dormont; P Tiollais; M L Michel
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.